Biosergen AB (FRA:8N1) Total Equity : €1.03 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Total Equity?

Biosergen AB's total equity for the quarter that ended in Sep. 2024 was €1.03 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biosergen AB Total Equity Historical Data

The historical data trend for Biosergen AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Total Equity Chart

Biosergen AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Equity

-1.07

1.97

2.07

0.19

Biosergen AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Equity	Get a 7-Day Free Trial											0.63	0.19	1.89	1.37	1.03

Biosergen AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biosergen AB's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	0.644	-	0.455
	=	0.19

Biosergen AB's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2024 )	-	Total Liabilities(Q: Sep. 2024 )
	=	1.282	-	0.251
	=	1.03

Biosergen AB Total Equity Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosergen AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

BIOSGN:Sweden

Address

Fogdevreten 2, Solna, SWE, 17165

Website

https://www.biosergen.net

Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines